期刊
ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW
卷 6, 期 3, 页码 129-133出版社
RADCLIFFE CARDIOLOGY
DOI: 10.15420/aer.2017:16:1
关键词
Leadless pacemaker therapy; retrieval; end-of-life management; Micra Transcatheter Pacing System; Nanostim Leadless Cardiac Pacemaker; transvenous pacemaker
资金
- Boston Scientific
- Abbott
- Medtronic
The clinically available leadless pacemakers for patients with a single-chamber pacing indication have shown to be safe and effective. However, the optimal end-of-life strategy of this novel technique is undefined. Suggested strategies comprise of (a) placing an additional leadless device adjacent to the leadless pacemaker, or (b) retrieving the non-functioning leadless pacemaker and subsequently implanting a new device. Although initial studies demonstrate promising results, early experience of acute and mid-term retrieval feasibility and safety remains mixed. We suggest that the approach of leadless pacemaker retrieval is more appealing to limit the amount of non-functioning intracardiac hardware. In addition, potential risks for device-device interference, and unknown long-term complications associated with multiple intracardiac devices are prevented. The potential inability to retrieve chronically implanted leadless pacemakers limits the application of this novel technology. Therefore, long-term prospective analysis is required to define the most optimal end-of-life strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据